To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel treatment.
Patients and methods
The TheraP trial (ANZUP 1603) is an open-label, randomized, stratified, two-arm multicentre phase 2 trial comparing the activity and safety of cabazitaxel chemotherapy vs 177 Lu-PSMA-617 therapy in the treatment of men with mCRPC. Key eligibility criteria include prior docetaxel chemotherapy, rising prostate-specific antigen (PSA) level, sufficient PSMA avidity, as defined by centrally reviewed 68 Ga-PSMA-11 and fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with no discordant FDG-avid PSMA-negative sites of disease. Patients in the control group receive standard treatment with cabazitaxel (20 mg/m 2 ) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles. Patients in the experimental group receive 177 Lu-PSMA-617 (8.5 GBq decreasing by 0.5 GBq per cycle) i.v. every 6 weeks, for up to a maximum of six cycles. In the event of an exceptional response as defined on centrally reviewed post-therapy singlephoton emission CT imaging, treatment will be suspended but can recommence on progression. The trial aims to include 200 patients who will be centrally randomized to one of the two treatment groups, in a 1:1 ratio. The primary endpoint is PSA response. Secondary endpoints are overall survival, progression-free survival (PFS), radiographic PFS, PSA PFS, objective tumour response, pain response, pain PFS, health-related quality of life, and frequency and severity of adverse events. The treatment and outcomes of patients excluded on the basis of low PSMA avidity or discordant FDG-avid disease on screening 68 Ga-PSMA-11 and Fluorine-18 ( 18 F)-FDG-PET/CT scan will also be assessed. Enrolment in the study commenced on 29 January 2018.
Introduction
Globally, prostate cancer is the second most frequently diagnosed cancer in men and is the fifth major cause of mortality [1] . Although localized prostate cancer may be cured with radiotherapy or surgery, many patients will go on to develop metastatic disease [2] . Standard initial treatment for patients with metastatic disease includes: androgen deprivation therapy using either LHRH agonists or antagonists or surgical castration; anti-androgens, such as bicalutamide; abiraterone, which blocks endogenous androgen synthesis [3] ; and docetaxel, a taxane chemotherapy [4] . Although a highly effective therapy, the median duration of response to castration is only approximately 2 years [5] , and patients eventually develop resistance, leading to disease progression and metastatic castration-resistant prostate cancer (mCRPC). Effective agents in mCRPC include abiraterone [6] , enzalutamide [7] , cabazitaxel [8] , sipuleucel-T [9] and, in bone-only disease, radium-223 dichloride [10] .
Prostate cancer is radio-responsive and external beam radiotherapy is a proven curative method for the treatment of localized prostate cancer. Radiation therapy is also effective as a palliative measure for localized metastatic disease. Radionuclide therapy uses systemically administered tumourtargeting agents to deliver therapeutic radiation to sites of metastatic prostate cancer. A key benefit of this approach is the ability to select patients, using positron emission tomography (PET), who are likely to benefit by visualizing those with high uptake. Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, has emerged as a favourable target as it is over-expressed in most prostate cancers, especially in metastatic, castration-resistant disease [11, 12] . The expression of PSMA in non-prostate tissues is limited mainly to the small intestine, proximal renal tubules and lacrimal and salivary glands. In these tissues PSMA is expressed at levels 100-1000 times lower than in the prostate [13, 14] . Following ligand binding to PSMA, heterodimerization occurs and is followed by rapid internalization of the ligand receptor complex [15] .
Gallium-68 PSMA-11/Lutetium-177 PSMA-617 Theranostics PSMA-11 and PSMA-617 are small molecules that bind with high affinity to the extracellular domain of PSMA. They are labelled with gallium-68 ( 68 Ga) and lutetium-177 ( 177 Lu) for PET imaging and radionuclide therapy, respectively, and both have high tumour uptake and rapid plasma clearance. Beta particles emitted from 177 Lu have a short-range of~1 mm, enabling delivery of high doses of radiation to tumours whilst minimizing damage to surrounding normal tissues. Demonstration of high uptake on 68 Ga-PSMA-PET is used for selection of patients for 177 Lu-PSMA therapy. A number of retrospective studies with substantial variability in treatment regimens have demonstrated favourable PSA responses of >50% in 31-72% of heavily pre-treated patients with mCRPC [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Hofman et al. [28] recently published a single-arm, singlecentre prospective study of 30 patients with mCRPC. Patients enrolled in that study had progressive disease after standard therapies, including taxane-based chemotherapy and secondgeneration anti-androgens. In all, 87% had received ≥1 line of prior chemotherapy (80% docetaxel and 47% cabazitaxel) and 83% had received prior abiraterone acetate and/or enzalutamide. Patients underwent a screening PSMA and fluorodeoxyglucose (FDG)-PET/CT to confirm high PSMA expression at all sites of disease. Patients received up to four cycles of 177 Lu-PSMA-617 i.v. every 6 weeks. The primary endpoint of PSA reduction ≥50% was achieved in 57% of patients (95% CI 37-75). Clinically meaningful improvements in pain severity and interference scores were observed. The median PSA progression-free survival (PFS) time was 7.6 months (95% CI 6.3-9.0) and overall survival (OS) was 13.5 months (95% CI 10.4-22.7).
The expected toxicities following 177 Lu-PSMA-617 primarily relate to radiation damage to normal tissues that have PSMA expression, including the salivary and lacrimal glands and kidneys, or crossfire effects on adjacent tissues from tumour uptake, such as in the bone marrow. In the phase 2 study, the most common toxicities were grade 1 xerostomia (87%) and grade 1-2 transient nausea (50%), as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 3-4 thrombocytopaenia or anaemia attributed to 177 Lu-PSMA-617 occurred in~10% of patients. No immediate acute severe adverse effects or anaphylaxis from the i.v. administration of 177 Lu-PSMA-617 have been described.
Rationale for the Comparator Arm
Cabazitaxel is a tubulin-binding taxane drug with anti-tumour activity in docetaxel-resistant cancers. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment, resulting in a 30% reduction in the risk of death and an improved median OS compared with mitoxantrone [8] . Generally, cabazitaxel is well tolerated in men with mCRPC and is a standard-of-care therapy in this population who have progressed on docetaxel. Data presented from the PROSELICA trial showed non-inferiority of the 20 mg/m 2 dose compared to the standard 25 mg/m 2 starting dose used in the TROPIC trial in terms of OS [8] . PFS was also similar between the two doses. The higher dose demonstrated a higher numerical PSA response rate in the higher dose arm but also significantly higher toxicity, in particular grade 3 or 4 toxicity. The 20 mg/ m 2 dose is now considered an appropriate starting dose for men considering cabazitaxel in the mCRPC setting.
TheraP Clinical Trial Overview
The TheraP clinical trial is an open-label, randomized, stratified, two-arm, multicentre, phase 2 trial to determine the efficacy and safety of 177 Lu-PSMA-617 compared with cabazitaxel chemotherapy in the treatment of men with mCRPC. Patients are randomized centrally to one of two treatment groups in a 1:1 ratio, stratified by disease burden (>20 sites vs ≤20 sites as measured on 68 Ga-PSMA-11 PET/ CT), prior enzalutamide or abiraterone treatment, and study site. The study schema is shown in Fig. 1 . Tertiary objectives are to determine the associations between 68 Ga-PSMA-11 PET/CT, Fluorine-18 ( 18 F)-FDG-PET/CT, baseline characteristics, and outcomes. The trial will also assess associations between clinical outcomes and possible prognostic and/or predictive biomarkers including circulating tumour DNA.
Additionally, patients who have been excluded from the study on the basis of low PSMA avidity or discordant FDGavid disease on screening 68 Ga-PSMA-11 and 18 F-FDG PET/ CT, respectively, will also have their treatment and outcomes assessed [29] .
Patients and Methods
The target population for the present study is men with mCRPC suitable for chemotherapy with cabazitaxel. The inclusion and exclusion criteria are listed in Table 1 . After registration, all patients undergo 68 Ga-PSMA-11 and 18 F-FDG PET/CT at baseline. The standard treatment group (Arm A) is cabazitaxel, given i.v. every 21 days at a dose of 20 mg/m 2 , for up to a maximum of 10 cycles. Prednisolone 10 mg orally daily will be administered throughout treatment with Study treatment should be planned to start within 21 days after randomization. Patients in both groups continue treatment with an LHRH agonist (or surgical castration) as required background treatment, as per standard of care.
Dose Delays and Modifications
The study allows patients who exhibit an exceptional response to 177 Lu-PSMA-617 to suspend treatment. An exceptional response is defined on the 24-h post treatment single-photon emission CT (SPECT)/CT as a marked reduction in uptake at all sites of disease with minimally avid or non-PSMA-avid disease. Patients who subsequently experience disease progression may be considered for re-treatment with 177 Lu-PSMA-617 if they had received <6 doses of 177 Lu-PSMA-617 and have symptomatic progression, PSA progression or radiological progression. These patients would require repeat imaging with 68 Ga-PSMA-11 PET/CT and FDG PET/CT prior to re-treatment. Exceptional responders with FDG-positive but PSMA-negative sites of disease would not be eligible for re-treatment.
Patients who develop a dose-limiting toxicity attributable to 177 Lu-PSMA-617 are to receive a 20% reduction in dose for their following cycle of treatment. Dose-limiting toxicities include any one of the following:
• Nadir platelet count <100 9 10 9 /L • Nadir neutrophil count <1.0 9 10 9 /L • Grade 2 dry mouth, or worse • Grade 2 dry eyes, or worse • Other significant dose-related toxicities, i.e. adverse events of grade 3 or worse For 177 Lu-PSMA-617, treatment would generally be withheld during adverse events of severity grade 3-4, with the exception of fatigue or lymphocytopaenia, and not restarted until the adverse event has resolved to grade 0-2.
The cabazitaxel treatment arm allows specified dose modification and treatment delays for grade 3-4 toxicities related to myelosuppression, hepatic dysfunction, stomatitis, peripheral neuropathy, hypersensitivity reactions and diarrhoea. Two dose reductions of cabazitaxel are allowed (15 and 10 mg/m 2 ). Treatment would be withheld during grade 3-4 adverse events, and not restarted until the adverse event has resolved to grade 0-1. The maximum delay for cabazitaxel is 3 weeks. No re-escalations of 177 Lu-PSMA-617 or cabazitaxel are allowed in the trial.
Treatment Discontinuation
Reasons for discontinuation of study include development of unacceptable toxicity, treatment no longer in the patient's best interest, occurrence of an exclusion criterion affecting patient safety, use of a prohibited treatment, significant protocol noncompliance, patient decision or evidence that the patient is no longer gaining clinical benefit. In addition, 177 Lu-PSMA-617 will be discontinued for unequivocal progression or delay of treatment for >16 weeks from the planned day of treatment. Cabazitaxel will be discontinued for progressive disease on imaging or symptomatic deterioration, or delays of treatment for >3 weeks from planned day of next cycle.
Assessments
During the study treatment, clinical assessments, including health-related quality of life and PSA testing, will be conducted every 3 weeks and at least every 4 weeks after study treatment until radiological progression. Imaging with CT and bone scan will be performed every 12 weeks for all patients. Those randomized to the 177 Lu-PSMA-617 arm of the study will have a PSMA SPECT/CT encompassing the neck, chest, abdomen and pelvis 24 h (AE4 h) after each treatment with 177 Lu-PSMA-617. The annotated schedule of assessments is summarized in Table 2 .
Nuclear Medicine Quality Assurance and Radiopharmaceutical Production
Prior to beginning enrolment, all sites will be certified by an independent review provided by the Australasian Radiopharmaceutical Trials Network (ARTnet). This will include certification of 68 Ga-PSMA-11 and 177 Lu-PSMA-617 production and 68 Ga PET/CT camera validation. The 68 Ga-PSMA-11 quality control parameters have been replicated from the Movember/PCFA ProPSMA study [30, 31] . 68 Ga-PSMA-11 administration and PET/CT acquisition are standardized across sites according to the study nuclear medicine manual. 177 Lu-PSMA-617 is compounded on-site by a qualified radiopharmacist or radiochemist using a standardized technique. The minimum quality control includes tests for radionuclidic purity, radiochemical purity using high-pressure liquid chromatography and thin-layer chromatography. 177 Lu-PSMA-617 is administered as an outpatient procedure with the patient observed until safe for discharge according to local radiation protection and Australian Radiation Protection and Nuclear Safety Agency guidelines. As a minimum, patients must be below 25 lSv/h at 1 m or 9 lSv/h at 2 m at the time of discharge. Each patient receives study radiation safety instructions prior to discharge.
During enrolment, all 68 Ga-PSMA-11 and 18 F-FDG PET/CT and post-therapy SPECT/CT procedures in the event of an exceptional response are subject to central review. The Web-Based Imaging Diagnosis by Expert Network (WIDEN) system co-ordinated through a core imaging laboratory at the Peter MacCallum Cancer Centre is used for image exchange, workflow control, central review and consensus creation [32] . Central review will be blinded to the local review and conducted by a multicentre team. Discordance between local and central review will trigger a second central review that will determine final eligibility; this reviewer will be unblinded and discuss findings with the local and first central reviewer.
Statistical Considerations
The primary endpoint for the present study is PSA response rate, defined as the proportion of patients in each group with a PSA reduction of ≥50% from baseline. The planned sample size of 200 patients randomized in 1:1 ratio will provide 80% power to detect a true absolute difference of 20% in the PSA response rate from 40% in those allocated to cabazitaxel, to 60% in those allocated 177 Lu-PSMA-617, with a two-sided type 1 error of 5% and an allowance of 3% for ineligible and/ or unevaluable patients.
For PFS, this sample size also provides 80% power to detect a true hazard ratio of 0.65, assuming a median PFS of 3 months in those allocated to cabazitaxel, 24 months for accrual, an additional 6 months for follow-up, and a twosided type 1 error rate of 5%.
The study has 80% power to detect a true hazard ratio for OS of 0.65 after 170 events.
The estimates of PSA response, median PFS and median OS for cabazitaxel are informed by the results of the TROPIC study [8] . The PSA response estimate for 177 Lu-PSMA-617 was informed by early data from the Peter MacCallum Cancer Centre prospective phase 2 trial [28] . The hypothesized magnitude of the additional benefit to these endpoints with 177 Lu-PSMA-617 are judged to be clinically plausible and worthwhile.
Analysis Plan
Analysis of efficacy endpoints will be undertaken on patients in the full analysis set, based on intention-to-treat. A sensitivity analysis using a per protocol analysis set may be performed on efficacy endpoints. The safety population will comprise all randomized patients who received at least one administration of study medication. Patients will be analysed according to the regimen they actually received for the purposes of the safety analysis. All P values and CIs will be two-sided.
The primary analysis will be a comparison of the treatment groups on PSA response rate using a Cochran-Mantel-Haenszel chi-squared test accounting for the stratification factors used at randomization. Other binary endpoints (e.g. pain response) will be analysed in the same way.
Point estimates for time-to-event endpoints will be estimated using the Kaplan-Meier method with appropriate CIs. Kaplan-Meier curves will be produced to summarize the distribution of the time-to-event data. A log-rank test accounting for stratification factors will be used to compare time-to-event endpoints between groups. Cox proportional hazards regression will also be applied to the time-to-event to estimate hazard ratios with CIs. The analysis of safety data will be principally descriptive in nature. The relevant linear modelling approach will be used to address tertiary objectives, and identify prognostic and predictive factors. These tertiary analyses will include a comparison, adjusted for potential confounders, between patients randomized to cabazitaxel and patients with low PSMA avidity or discordant FDG-avid disease on screening 68 Ga-PSMA-11 and FDG PET/CT who are not randomized but go on to receive cabazitaxel.
Results
The study endpoints are summarized in Table 3 . The study was opened to enrolment on 29 January 2018. At time of this publication, the study has almost completed recruitment.
Discussion
177 Lu-PSMA-617 is an exciting new class of therapeutics in prostate cancer. Uniquely, the theranostic concept enables both patient selection and visualization of the therapeutic response using nuclear medicine imaging [33] . To date, the promising activity of 177 Lu-PSMA-617 has been demonstrated primarily in retrospective studies and an investigator-initiated prospective, single-arm, single-centre phase 2 study. The comparative activity of 177 Lu-PSMA-617 to standard therapies is still unknown. This will be the first multicentre randomized study to determine the activity of 177 Lu-PSMA-617 compared with cabazitaxel chemotherapy in men with mCRPC. Candidates for this trial will need to have progressed on docetaxel, but may or may not have received treatment with the newer anti-androgen therapies, such as abiraterone and/or enzalutamide.
Variations of the study design and the inclusion criteria were carefully considered in the development of the protocol. For example, the study team felt it was important to compare 177 Lu-PSMA-617 with an active therapy. Given that existing experience with 177 Lu-PSMA-617 has predominantly been within a heavily pre-treated population of patients with mCRPC, cabazitaxel was selected as the most appropriate standard therapy comparator arm. Additionally, there was careful consideration of whether or not eligible patients should have progressed on the new-generation hormone therapies, such as enzalutamide and abiraterone. While there are studies to suggest that there may be a synergistic effect of 177 Lu-PSMA-617 therapy with the new-generation hormonal therapies [34] , this has only been reported in an in vitro [35] and murine model [19] , with anecdotal human data on the efficacy and tolerability of the combination. Thus, for the present study, we felt it was important to establish the comparative activity of the single agent 177 Lu-PSMA-617 first, before pursuing other hypotheses of interest.
The trial represents a close collaboration between nuclear medicine, medical oncology and radiation oncology specialities. Based on safety data from the phase II data [36] , up to six cycles rather than four cycles of 177 Lu-PSMA-617 will be administered. The study also uses standardized quantitative parameters from PSMA PET to determine eligibility. To ensure accurate quantification, all sites undergo stringent qualification of radiopharmaceutical production and PET/CT acquisition. Another novel element of the study is the ability for exceptional responders to suspend 177 Lu-PSMA-617 therapy and re-commence upon progression.
The trial will assess the primary endpoint of PSA response rate, which is an appropriate signal of activity in the advanced prostate cancer setting and appropriate for a phase 2 study. At the time of protocol development, radiological PFS data or OS data for 177 Lu-PSMA-617 were not well defined, whereas PSA response rate data were available. This enabled us to make a meaningful sample size calculation. Secondary endpoints in this trial of PFS and OS are, however, of great interest. The trial will also obtain data on pain response, adverse events and health-related quality of life which are important considerations in this patient cohort who are usually symptomatic from their disease or treatmentrelated effects [37] . Additionally, this study will provide outcome and treatment data on patients not eligible for the study on the basis of low PSMA avidity or discordant FDG disease at screening [28] , compared to patients randomized to cabazitaxel or 177 Lu-PSMA-617. This may allow identification of new prognostic and predictive factors within this population of men with mCRPC.
Importantly, results from this study will provide a greater understanding of the safety and activity of 177 Lu-PSMA-617 in progressive mCRPC, with potential to influence the standard of care in this population. It may also pave the way for studying the efficacy of this treatment in other stages and treatment settings of prostate cancer [38] . Finally, the consent process for this trial will allow the opportunity for patients to enrol in translational sub-studies, which has the potential to identify additional biomarkers of 177 Lu-PSMA-617 and cabazitaxel activity.
Collaborators and Study Organization
The TheraP study is a locally developed and investigatorinitiated collaborative group study sponsored by ANZUP. The coordination, monitoring, data acquisition and management and statistical analysis is performed by the NHMRC Clinical Trials Centre. The TheraP Trial Management Committee oversees study planning, monitoring, progress, review of information from related research, and implementation of recommendations from other study committees and external bodies (e.g. ethics committees). The ANZUP Independent Data Safety Monitoring Committee provides independent oversight of the trial, to monitor the accrual, event rates, and key safety endpoints in accordance with the charter.
The study chair is Prof. 1 Overall survival, defined as the interval from the date of registration to date of death from any cause, or the date of last known follow-up alive 2 Progression-free survival, defined as the interval from date of randomization to the date of first evidence of PSA progression, pain progression, radiographic progression, or death from any cause, whichever occurs first, or the date of last known follow-up without progression 3 Radiographic progression-free survival, defined as the interval from the date of randomization to the date of first evidence of radiographic progression or the date of last known follow-up without radiographic progression 4 PSA progression-free survival, defined as the interval from the date of randomization to the date of first evidence of PSA progression or the date of last known follow-up without PSA progression 5 Objective tumour response, defined as the proportion of patients in each group with a confirmed complete response or partial response divided by the number of patients in each group 6 Pain response, as measured 
